SCHEMBL536873

SCHEMBL536873

CC(=O)OCC(CO)c1ccc(Br)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.43
PRKCA P17252 2/20 0.42
PRKCD Q05655 2/20 0.42
NPSR1 Q6W5P4 2/20 0.38
CYP2D6 P10635 2/20 0.38
PKM P14618 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALOX5 P09917 1/20 0.36
CNR1 P21554 1/20 0.36
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
S1PR4 O95977 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
S1PR1 P21453 1/20 0.34
MAPK1 P28482 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2602795 0.91 CYP1A2 (0.47) CYP1A2NPSR1CYP2D6PKMSMN1; SMN2
SCHEMBL27532767 0.83 BRD4 (0.43) CYP1A2PRKCAPRKCDNPSR1CYP2D6
SCHEMBL27388380 0.83 BRD4 (0.43) CYP1A2PRKCAPRKCDNPSR1CYP2D6
SCHEMBL2705027 0.83 CYP1A2 (0.56) CYP1A2PRKCAPRKCDNPSR1CYP2D6
SCHEMBL2705028 0.83 CYP1A2 (0.56) CYP1A2PRKCAPRKCDNPSR1CYP2D6
SCHEMBL8103307 0.83 CYP1A2 (0.56) CYP1A2PRKCAPRKCDNPSR1CYP2D6
SCHEMBL8193963 0.82 PRKCA (0.50) PRKCAPRKCDNPSR1SMN1; SMN2MEN1
SCHEMBL8193959 0.82 PRKCA (0.50) PRKCAPRKCDNPSR1SMN1; SMN2MEN1
SCHEMBL27900437 0.79 CYP1A2 (0.46) CYP1A2NPSR1CYP2D6ALOX5ALDH1A1
Carbamic Acid SCHEMBL8934351 0.79 CYP1A2 (0.60) CYP1A2PRKCAPRKCDNPSR1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9108957-B2 3-[1,4]oxazepane-4-pyrimidone derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-08-18 US disclosed
US-9108957-B2 3-[1,4]oxazepane-4-pyrimidone derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-08-18 US disclosed
US-9108957-B2 3-[1,4]oxazepane-4-pyrimidone derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-08-18 US disclosed
US-20120095216-A1 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES SANOFI (FR) 2012-04-19 US disclosed
US-20120095216-A1 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES SANOFI (FR) 2012-04-19 US disclosed
US-20120095216-A1 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES SANOFI (FR) 2012-04-19 US disclosed
EP-2414349-A1 3-Ý1,4¨OXAZEPANE-4-PYRIMIDONE DERIVATIVES Mitsubishi Tanabe Pharma Corporation (JP) 2012-02-08 EP disclosed
WO-2010114179-A1 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-10-07 WO disclosed
WO-2010114179-A1 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095216-A1 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES PSEN1, MAPT, PSEN2 CYP1A2 2517/4885PRKCA 299/4885PRKCD 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.